1. Introduction

Pharmacy chain coordination refers to arrangements or coordinated conduct among pharmacy chains, independent pharmacies, wholesalers, manufacturers, purchasing groups, or pharmacy platforms that may reduce competition in the retail or distribution of medicines.

The conduct may involve:

• coordination of retail prices;
• allocation of geographic territories or customers;
• collective refusal to deal with suppliers;
• exchange of commercially sensitive information;
• coordinated purchasing or tendering;
• exclusive distribution arrangements;
• restrictions on online pharmacy sales;
• agreements concerning discounts, rebates, or reimbursement rates;
• coordination through pharmacy associations or buying groups; and
• mergers or acquisitions that consolidate competing pharmacy chains.

Competition law generally distinguishes legitimate commercial cooperation from coordination that substitutes collective decision-making for independent competitive conduct.

2. Relevant Competition-Law Issues

Pharmacy-chain coordination can potentially fall into two broad categories:

A. Horizontal coordination

This occurs between competitors at the same level of the supply chain.

Examples:

• Pharmacy Chain A and Pharmacy Chain B agree to maintain the same retail price.
• Several pharmacy chains agree not to enter one another's territories.
• Competing pharmacies coordinate bids for hospital or government contracts.
• Competitors exchange future pricing information.

Such conduct can amount to a cartel or concerted practice.

B. Vertical coordination

This occurs between businesses at different levels.

Examples:

• pharmaceutical manufacturer → wholesaler → pharmacy;
• wholesaler → pharmacy chain;
• pharmacy platform → participating pharmacies.

Potential issues include:

• resale-price maintenance;
• exclusive dealing;
• territorial restrictions;
• customer restrictions;
• online-sales restrictions;
• loyalty rebates; and
• foreclosure of rival pharmacies.

3. Price Coordination Between Pharmacy Chains

One of the most serious concerns arises when competing pharmacies coordinate the prices charged to consumers.

For example:

Chain A, Chain B and Chain C independently compete for consumers but agree that specified prescription or non-prescription medicines will be sold at predetermined margins.

The competition concern is particularly strong where the agreement concerns:

• current prices;
• future prices;
• minimum prices;
• discounts;
• margins;
• dispensing fees; or
• reimbursement terms.

Direct price fixing

An explicit agreement to fix prices is ordinarily treated as a classic form of horizontal restraint.

Indirect coordination

Coordination need not always take the form of a written agreement. Evidence can include:

• meetings;
• communications;
• common pricing formulas;
• exchange of future pricing intentions;
• coordinated announcements;
• identical commercially sensitive instructions; and
• conduct that cannot reasonably be explained by independent commercial decisions.

4. Information Exchange Among Pharmacy Chains

Pharmacy chains may legitimately collect market information.

However, exchanging strategically sensitive information between competitors can facilitate coordination.

Potentially problematic information includes:

• future prices;
• planned discounts;
• purchasing volumes;
• margins;
• inventory levels;
• customer-specific information;
• tender strategies;
• future expansion plans; and
• negotiations with suppliers.

The risk increases when the information is:

1. individualized;
2. recent or forward-looking;
3. commercially sensitive; and
4. exchanged between actual competitors.

Aggregated historical market statistics are generally less problematic than detailed future pricing information.

5. Pharmacy Buying Groups

Pharmacies sometimes establish purchasing groups to obtain better terms from pharmaceutical manufacturers and wholesalers.

Such cooperation can generate legitimate efficiencies through:

• economies of scale;
• reduced transaction costs;
• lower procurement costs;
• improved logistics;
• better inventory management.

However, the arrangement may raise competition concerns if the purchasing group is used to:

• fix resale prices;
• exclude rival suppliers;
• boycott particular manufacturers;
• coordinate retail prices;
• divide markets; or
• exchange sensitive information beyond what is necessary for joint purchasing.

The legal analysis therefore requires examination of both competitive harm and legitimate efficiencies.

6. Collective Boycotts

A group of pharmacy chains may collectively refuse to purchase from or supply a particular company.

For example:

Several large pharmacy chains jointly agree not to stock medicines supplied by a particular manufacturer unless the manufacturer accepts specified commercial conditions.

Such conduct may become problematic where the participating pharmacies possess substantial collective market power.

Important questions include:

• Why was the boycott adopted?
• Was there an agreement among competitors?
• Does the group collectively possess significant purchasing or selling power?
• Is the conduct capable of excluding the targeted supplier?
• Was the restriction reasonably necessary for legitimate cooperation?

7. Geographic Market Allocation

Competitors may also agree not to compete in each other's geographic territories.

Example:

Chain A agrees to operate only in northern regions while Chain B agrees to stay in southern regions.

Such conduct eliminates competition between the parties.

Market allocation can involve:

• geographic territories;
• particular customers;
• hospitals;
• insurers;
• corporate clients;
• government contracts; or
• particular product categories.

This is especially concerning where the arrangement prevents new entry or protects established pharmacy chains from competitive pressure.

8. Tender Coordination

Pharmacy chains frequently participate in procurement contracts involving:

• hospitals;
• government agencies;
• insurance networks;
• healthcare institutions;
• corporate health programmes.

Coordination can take the form of:

• bid rotation;
• cover bidding;
• bid suppression;
• allocation of contracts;
• advance agreement on winning bidders; or
• exchange of tender prices.

Example

Five pharmacy chains participate in a government medicine-supply tender. Before submitting bids, they agree which chain will win and submit artificially high bids to create the appearance of competition.

This is a classic form of bid-rigging.

9. Resale-Price Maintenance

Pharmacy chains may also be subject to vertical restrictions imposed by pharmaceutical manufacturers.

Suppose a manufacturer tells pharmacies:

"You must not sell this medicine below ₹500."

If the arrangement effectively prevents independent discounting, competition authorities may examine it as resale-price maintenance.

The analysis normally considers:

• market power;
• nature of the restriction;
• enforcement mechanism;
• duration;
• coverage;
• effect on intra-brand competition; and
• possible inter-brand efficiencies.

10. Exclusive Dealing

A pharmaceutical manufacturer might require a pharmacy chain to purchase exclusively from it.

Alternatively, a major pharmacy chain may require suppliers to provide medicines exclusively through that chain.

Potential competition concerns arise where exclusivity:

• covers a substantial share of the market;
• lasts for a long period;
• prevents rival suppliers from obtaining distribution;
• raises entry barriers; or
• combines with significant market power.

Exclusive arrangements are not automatically unlawful; their competitive effects must be examined in context.

11. Online Pharmacy Coordination

The growth of online pharmacies creates additional competition issues.

Potential restrictions include:

• agreements preventing pharmacies from selling online;
• restrictions on price comparison;
• platform parity clauses;
• restrictions on third-party marketplaces;
• coordinated online pricing;
• algorithmic price coordination; and
• restrictions on digital advertising.

An online pharmacy platform that controls access to a substantial customer base may also raise platform-access and self-preferencing issues.

12. Pharmacy Chain Mergers

Competition concerns may arise even without an explicit coordination agreement.

A merger between two major pharmacy chains can reduce the number of competitors in a local market.

Authorities may examine:

• market concentration;
• local geographic markets;
• number of competing pharmacies;
• closeness of competition;
• barriers to entry;
• purchasing power;
• supplier relationships;
• effects on medicine prices; and
• effects on service quality.

Pharmacy markets can be particularly sensitive to local concentration, because consumers may have limited practical alternatives in a particular locality.

13. Relevant Case Laws

1. United States v. Apple Inc., 791 F.3d 290 (2d Cir. 2015)

Facts

Apple was accused of participating in a conspiracy with major book publishers concerning the pricing of e-books.

Principle

The case demonstrates that coordination involving a platform and multiple market participants can constitute unlawful horizontal price coordination even where the structure involves several contractual relationships.

Relevance to pharmacy chains

A pharmacy platform coordinating pricing among competing pharmacies could similarly attract scrutiny where the arrangement facilitates coordinated retail pricing.

2. FTC v. Surescripts, LLC, 81 F.4th 1246 (D.C. Cir. 2023)

Facts

The U.S. Federal Trade Commission challenged alleged exclusionary conduct involving electronic prescribing services.

Principle

The case illustrates how conduct in a healthcare-related digital market can raise competition concerns where market power and exclusionary strategies restrict competitive alternatives.

Relevance

Modern pharmacy competition increasingly depends upon digital prescription and transaction infrastructure. Control over such infrastructure can therefore have competition-law implications beyond conventional retail pricing.

3. FTC v. Actavis, Inc., 570 U.S. 136 (2013)

Facts

The case concerned settlements between pharmaceutical manufacturers involving patent litigation and payments to generic competitors.

Principle

The Supreme Court held that certain pharmaceutical patent settlements may require antitrust scrutiny where the settlement potentially delays generic competition.

Relevance

Although not a pharmacy-chain case, it demonstrates the importance of maintaining competitive conditions in pharmaceutical distribution and access to lower-cost alternatives.

4. Leegin Creative Leather Products, Inc. v. PSKS, Inc., 551 U.S. 877 (2007)

Facts

A manufacturer imposed minimum resale prices on retailers.

Principle

The U.S. Supreme Court held that vertical minimum resale-price agreements are not automatically unlawful per se under federal antitrust law and are generally examined under the rule of reason.

Relevance

A pharmaceutical manufacturer imposing minimum retail prices on pharmacies may therefore require analysis of market structure and competitive effects rather than automatic characterization solely from the existence of the vertical restriction.

5. FTC v. Indiana Federation of Dentists, 476 U.S. 447 (1986)

Facts

A professional association restricted the provision of information used by insurers in evaluating dental claims.

Principle

A professional association cannot use collective organization as a means of suppressing competition.

Relevance

Pharmacy associations or collective pharmacy organizations may face similar concerns if association rules facilitate collective restrictions on suppliers, insurers or competing pharmacies.

6. National Collegiate Athletic Association v. Board of Regents of the University of Oklahoma, 468 U.S. 85 (1984)

Facts

The NCAA imposed restrictions on television broadcasting of college football games.

Principle

An organization containing competitors cannot automatically justify restraints merely because the restriction is adopted through a collective organization.

Relevance

A pharmacy purchasing or professional association cannot necessarily immunize restrictive coordination merely by characterizing the conduct as an association decision.

7. FTC v. Superior Court Trial Lawyers Association, 493 U.S. 411 (1990)

Facts

Criminal-defense lawyers collectively agreed to stop accepting court-appointed cases until compensation increased.

Principle

Collective action by competitors to obtain higher compensation can constitute an unlawful restraint of trade.

Relevance

The case is useful by analogy for pharmacy associations or pharmacy chains collectively refusing to provide services or supply medicines in order to force a purchaser or insurer to accept coordinated commercial terms.

8. United States v. Socony-Vacuum Oil Co., 310 U.S. 150 (1940)

Facts

Oil companies participated in a scheme involving coordinated purchases and price stabilization.

Principle

Agreements among competitors designed to influence market prices can constitute unlawful price fixing.

Relevance

The foundational principle is relevant where competing pharmacy chains coordinate prices, discounts or margins.

14. Indian Competition-Law Framework

For India, pharmacy-chain coordination primarily falls under the Competition Act, 2002.

Section 3

Section 3 addresses agreements that cause or are likely to cause an appreciable adverse effect on competition.

Horizontal agreements between competitors can attract particularly serious scrutiny where they involve:

• price fixing;
• limiting supply;
• market sharing;
• bid rigging; or
• collusive tendering.

Section 4

Where a pharmacy chain possesses a dominant position, unilateral conduct may also be examined under Section 4.

Potential issues include:

• discriminatory conditions;
• denial of market access;
• unfair pricing;
• exclusionary discounts;
• tying;
• leveraging dominance into adjacent pharmacy markets.

Sections 5 and 6

These provisions become relevant where pharmacy-chain consolidation takes the form of a merger, acquisition or other combination meeting the statutory requirements.

15. Indian Case Law Relevant to Pharmacy Coordination

1. Excel Crop Care Ltd. v. Competition Commission of India

The Supreme Court dealt with cartel conduct and the interpretation of penalty principles under Indian competition law.

Relevance

The case demonstrates the seriousness with which coordinated conduct between competitors can be treated under Section 3, particularly where competitors collectively influence market conditions.

2. Rajasthan Cylinders & Containers Ltd. v. Union of India

The Supreme Court examined allegations of cartelisation in government procurement.

Principle

Parallel pricing or similar bids, without sufficient evidence of an agreement or concerted practice, do not automatically establish a cartel.

Pharmacy relevance

If several pharmacy chains independently quote similar prices to a hospital or government purchaser, similarity alone should not necessarily be treated as proof of coordination.

Evidence concerning communication, meetings, information exchange and coordinated conduct becomes important.

3. Competition Commission of India v. Coordination Committee of Artists and Technicians of West Bengal Film and Television

The Supreme Court examined collective action undertaken through associations.

Principle

An association cannot necessarily avoid competition-law scrutiny merely because restrictive conduct is adopted collectively.

Pharmacy relevance

Pharmacy associations or purchasing groups may be examined where collective decisions restrict competition between their members.

4. Builders Association of India v. Cement Manufacturers' Association

The CCI and appellate proceedings considered allegations concerning coordinated conduct among cement manufacturers.

Principle

Competition law examines whether competitors have engaged in coordinated conduct rather than merely whether they operate within the same industry.

Pharmacy relevance

Pharmacy chains similarly remain independent competitors and cannot use an industry association as a mechanism for coordinating commercial decisions.

5. Samir Agarwal v. Competition Commission of India

The Supreme Court considered allegations concerning algorithmically generated price similarities on ride-hailing platforms.

Principle

Parallel pricing or similar outcomes do not necessarily establish an agreement. There must be a sufficient evidentiary basis to connect the conduct to coordination.

Pharmacy relevance

Where different pharmacy chains independently use pricing software and prices become similar, competition authorities would need to examine whether the algorithms merely respond independently to market conditions or facilitate concerted conduct.

6. Kapoor Glass India Pvt. Ltd. v. Competition Commission of India

The matter concerned allegations of anti-competitive conduct and the evidentiary requirements surrounding cartelisation.

Principle

Competition authorities must assess the overall evidence and circumstances rather than infer an unlawful agreement solely from market similarity.

Pharmacy relevance

Similar prices among pharmacies may result from common supplier prices, regulated medicine prices, common costs or competitive market conditions. Those factors must be distinguished from actual collusion.

16. Distinguishing Legitimate Coordination from Anti-Competitive Coordination

The critical distinction is whether cooperation creates efficiencies while preserving independent competitive decision-making, or whether it replaces independent competition with coordinated conduct.

17. Factors Authorities May Examine

A competition authority examining pharmacy-chain coordination may consider:

Market structure

• Number of pharmacy chains;
• market shares;
• concentration;
• barriers to entry.

Conduct

• communications;
• contracts;
• association meetings;
• pricing data;
• procurement arrangements.

Economic evidence

• price movements;
• margins;
• discounts;
• purchasing patterns;
• tender outcomes.

Competitive effects

• higher medicine prices;
• reduced discounts;
• reduced availability;
• exclusion of independent pharmacies;
• reduced innovation;
• reduced consumer choice.

Countervailing considerations

• efficiencies;
• economies of scale;
• improved supply reliability;
• reduced transaction costs;
• quality improvements.

18. Compliance Measures for Pharmacy Chains

Pharmacy groups should establish strong competition-law compliance programmes.

Recommended measures

1. Prohibit agreements with competitors concerning prices.
2. Restrict exchange of competitively sensitive information.
3. Maintain clear agendas and minutes for trade-association meetings.
4. Train purchasing and pricing personnel.
5. Screen communications involving competitors.
6. Establish tender-participation protocols.
7. Review exclusive purchasing arrangements.
8. Review distribution and online-sales restrictions.
9. Conduct competition assessment before joint ventures.
10. Obtain legal review of industry-association initiatives.

Particular caution is required when competitors participate in the same purchasing group, digital platform or healthcare procurement programme.

19. Key Legal Tests

A pharmacy-chain coordination dispute can generally be analysed through the following sequence:

Identify the parties
↓
Determine whether they are competitors or vertically related
↓
Identify the agreement/conduct
↓
Determine the relevant product and geographic market
↓
Assess market power and concentration
↓
Determine whether the conduct is inherently restrictive or requires effects analysis
↓
Examine actual or likely competitive effects
↓
Consider efficiencies and objective justifications
↓
Determine appropriate competition-law response

20. Conclusion

Pharmacy chain coordination covers a wide range of conduct, from legitimate joint purchasing and logistics to potentially serious cartel behaviour. The principal risks arise where competing pharmacies coordinate prices, discounts, customers, territories, tenders, supply conditions or commercially sensitive information.

The same conduct may have different legal consequences depending on the market structure and jurisdiction. A purchasing consortium that produces genuine procurement efficiencies is fundamentally different from a group of pharmacy chains using the consortium to coordinate retail prices or exclude competitors.